Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Wednesday announced plans reduce its global workforce by approximately 9,000 of 78,400 positions, including around 5,000 in Denmark.

This move is part of a company-wide transformation aimed at simplifying its organisation, accelerating decision-making, and reallocating resources toward growth opportunities in diabetes and obesity.

The restructuring is expected to deliver annualised savings of DKK8bn by the end of 2026, which will be reinvested into R&D, commercial execution, and manufacturing scale-up. Implementation is set to begin immediately, with consultations and communications with affected employees to follow.

Novo Nordisk expects one-off restructuring costs of DKK8bn, including impairment charges, resulting in a 6-percentage-point reduction to the company's full-year 2025 operating profit growth outlook, now 4-10% at CER. Depreciation, amortisation, and impairment losses are expected to total around DKK21bn for 2025.

According to Novo Nordisk, this transformation addresses organisational complexity from rapid past growth and positions the company to reach millions of untreated patients while enhancing agility, performance culture, and cost efficiency.

(EUR1=DKK7.47)